In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Vijay Vaswani, Co-Founder & CEO at Omniscope.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Vijay, covering:

• How travel expands the mind and enables you to amplify your network
• The founding story of Omniscope and its mission of using tech to help unlock the immune system
• AI can read the immune system in HD, helping with clinical trials and predictive candidate selection
• How you should be thinking about AI for drug discovery and drug development
• And what the t-shirt he wears at work says on the front...

Vijay Vaswani views technology as fundamental to humanity. He has been involved in scaling companies such as Illumina and 10X Genomics. During his leadership at Siemens Healthineers and Meridian Biosciences, he acquired and commercialized disruptive diagnostic technologies. Vijay has also participated in important IPOs in the biotechnology industry and finds his passion in improving health through the application of technology.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

See you at BPI!

M2M host, Raman Sehgal will be attending the BPI event in Boston this September. The BPI team has given M2M listeners an exclusive discount code for event passes - enjoy 30% off using the code MOLECULE30 or follow this link: https://informaconnect.com/bioprocessinternational/?vip_code=MOLECULE30&utm_source=molecule2market&utm_medium=website

Don't miss out and we'll see you in September!

In this episode of Molecule to Market, you’ll go inside the global drug development and GMP Manufacturing space with David Staunton, Head of Life Sciences Transformation at Cognizant.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with David, covering:

• Why being a supplier is harder if you have not been on the client side
• An industry driven by change and the importance of digital strategy to drive business outcomes
• Why pharma companies need to be both big and fast to win
• How AI is accelerating promising molecules and leading to GMP Manufacturing and supply bottlenecks
• The future of deployable, modular factories to service population centers that provide better access to personalized medicines
• How generative AI is impacting the industry right now, and how will this evolve with the introduction of robots (or ‘cobots’)

David leads transformation and generative AI, collaborating closely with tier 1 pharma and biotech client teams worldwide. Over the last 25+ years, David has established and directed international teams, pioneering practical, proven, and innovative programs that revolutionize new product introduction (NPI) and GMP manufacturing & supply.

In consistent dialogue with CIOs, Global VPs of Engineering, Quality VPs, and Site Heads of GMP Manufacturing and Lab facilities, David leads the delivery of Transformation Services for Industry 4.0. David is an internationally recognized speaker on Industry 4.0 and has given lectures on various UCD Master’s Programmes.

LinkedIn: (6) David Staunton | LinkedIn

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency that helps companies differentiate, get noticed, and grow in the life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:

• Tom Willson, Vice President of Contract Manufacturing at Pfizer CentreOne
• Hanna Lesch, Chief Technology Officer at Exothera
• Stephen Grant, entrepreneurial advisor and angel investor

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, Hanna, and Stephen, covering:

• Unraveling the potential seismic shift in the pharmaceutical outsourcing industry; the BIOSECURE Act and its implications
• Will the BIOSECURE Act accelerate a trend toward a more regionalized approach to drug development and manufacturing?
• How Biotechs/CDMOs are going to adapt their strategies post BIOSECURE Act
• What impacts BIOSECURE will have on the supply chain

The BIOSECURE Act has the potential to significantly restrict the ability of biotechnology companies to collaborate with certain Chinese companies without losing the ability to contract with the US government. Our guests provide insightful perspectives on the potential implications of this legislation on the supply chain of life-saving drugs across America.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.